New York, NY
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)The End Fund Inc, founded in 2010, is a mid-sized nonprofit in the International Affairs sector that reported $62.7M in total revenue in fiscal year 2024. Revenue grew 11% year-over-year, indicating healthy expansion. Expenses of $74.2M exceeded revenue, resulting in a 18% operating deficit.
The END Fund's mission is to control and eliminate six neglected tropical diseases: river blindness, lymphatic filariasis, trachoma, schistosomiasis, intestinal worms, and visceral leishmaniasis.
The END Fund is a leading philanthropic community dedicated to ending six neglected tropical diseases that impact 1.65 billion people globally: intestinal worms, schistosomiasis, lymphatic...
The END Fund is a leading philanthropic community dedicated to ending six neglected tropical diseases that impact 1.65 billion people globally: intestinal worms, schistosomiasis, lymphatic filariasis, river blindness, trachoma, and visceral leishmaniasis. The END Fund efficiently puts private capital to work, advocating for neglected tropical disease programs that are innovative, integrated and cost-effective. We facilitate strong partnerships with the private sector, government partners, and local programmatic partners to collaboratively support national disease programs. This is done through a proven implementation model that is tailored to meet the needs of individual countries. The END Fund was established as a new model, the first of its kind in the neglected tropical disease field: a philanthropic fund that increases resources, coordination, and collaboration toward the goal of ending neglected tropical diseases, thereby reducing the physical, social, economic, and systemic impact of these diseases for hundreds of millions of people. Our model is designed to mobilize resources to close the neglected tropical disease funding gap through partnerships with global philanthropists and private-sector investors. By pooling funds, the END Fund helps activist-philanthropists make outsized impacts with their investments. Through collaboration with our programmatic partners, we help deliver treatment at scale, accelerate innovations that improve the efficiency of drug delivery, provide program oversight to monitor quality and impact, and bring together partners, advocates, and investors. Because we direct resources and training activities through local partners, who know the landscape and can go where international agencies cannot or will not, we operate successfully and with measurable impact in some of the world's most challenging environments due to war or instability. Our focus has always been on large-scale change and we are committed to investing in and alongside local governments, building in-country technical tools and skills, and incorporating neglected tropical diseases into national health agendas for solid local ownership. In close partnership with stakeholders across the global neglected tropical disease community, the END Fund: Identified gaps and opportunities, by understanding investment needs and gaps in funding for neglected tropical diseases, landscapes investable opportunities, and increases coordination among stakeholders. The END Fund also builds coalitions, by mobilizing and activating collaboration among country-level stakeholders, including ministries of health, programmatic partners, investors, etc. The END Fund designs programs by working with ministries of health and programmatic partners to expand data collection, mapping, and sector knowledge in order to identify compelling program opportunities. The END Fund trains partners by aiming to grow and strengthen the pool of partner organizations to assist local governments in the implementation of quality neglected tropical disease programs. The END Fund manages grants and provides technical support by conducting country program visits and provides partner support, technical assistance, and training as needed. In 2024, the END Fund supported the distribution of 247,323,479 NTD treatments with 152,630,533 people treated across 21 countries by 27 implementing partners. During the same period, 38,100 surgeries were conducted in 12 countries by 15 implementing partners and 1,198,935 health care workers trained across 24 countries by 31 implementing partners.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2024 | 2023 | Change | |
|---|---|---|---|
| Revenue | $62,672,882 | $56,392,358 | +0.1% |
| Expenses | $74,181,557 | $64,042,913 | +0.2% |
| Net Income | $-11,508,675 | $-7,650,555 | +0.5% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| ALAN MCCORMICK | VICE CHAIR | 1.0 |
Officer
Director
|
$0 | $0 | $0 |
| SCOTT POWELL | TREASURER (thru December 1, 2024) | 1.0 |
Officer
Director
|
$0 | $0 | $0 |
| Tsitsi Masiyiwa | CHAIR | 1.0 |
Officer
Director
|
$0 | $0 | $0 |
| CHRISTINE WACHTER CAMPBELL | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| ENGLISH SALL | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| MICHAEL HOFFMAN | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| MOSES BOCKARIE | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| DANIEL DALEY | SR VP of Finance and Admin (thru June 15, 2024), Acting COO (as of June 15, 2024) | 40.0 |
Officer
|
$373,799 | $3,159 | $376,958 |
| DIANA BENTON SCHECHTER | COO / BOARD SECRETARY (thru June 15, 2024) INTERIM CEO (as of June 15, 2024) | 40.0 |
Officer
|
$394,601 | $40,825 | $435,426 |
| ELLEN AGLER | CEO thru June 15, 2024 | 40.0 |
Officer
|
$284,219 | $33,017 | $317,236 |
| CAROLINE KARUTU | VP of Programs | 40.0 |
Highest
|
$259,477 | $21,027 | $280,504 |
| ELLIE DEHGHAN | Head of Legal & Global Operations | 40.0 |
Highest
|
$233,865 | $33,708 | $267,573 |
| MIREILLE MATHER | VP of Investor Relations | 40.0 |
Highest
|
$245,865 | $60,066 | $305,931 |
| MODUPEOLA ODUSOTE | Head of Culture & Talent | 40.0 |
Highest
|
$227,398 | $58,495 | $285,893 |
| SAMUEL MAYER | VP of Global Strategic Partnerships | 40.0 |
Highest
|
$267,765 | $16,938 | $284,703 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | $62,672,882 | $74,181,557 | $38,929,869 | $-11,508,675 |
| 2023 | $56,392,358 | $64,042,913 | $50,403,877 | $-7,650,555 |
| 2022 | $79,135,799 | $60,493,617 | $58,581,667 | $18,642,182 |
| 2021 | $35,034,243 | $36,973,338 | $37,486,570 | $-1,939,095 |
| 2020 | $22,787,083 | $28,854,476 | $39,399,933 | $-6,067,393 |
| 2019 | $44,978,754 | $31,011,608 | $45,414,106 | $13,967,146 |
Compare The End Fund Inc with other nonprofits in New York and across the country.